Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: A: Located at the C-terminus, the P1086fs+32X (3256InsG) mutation is caused by a guanosine insertion in the codon at position 3256 (2356InsG), which elicits a frameshift at proline 1086 and produces 32 new amino acids before a premature stop codon. The mutation is downstream of the cyclic nucleotide binding domain (cNBD) and produces a truncated channel subunit. The N-terminus contains the Per Arnt Sim domain (PAS) and a HA-tag. B: Sequences for Kv11.1-wt and Kv11.1-mut (P1086fs+32X) including the nonsense 32 amino acid sequence.

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Mutagenesis, Binding Assay, Sequencing

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: A: Immunoblot of equal amounts of protein lysates (25 µg) from HEK cells transfected with 1.0 or 2.0 µg of Kv11.1 cDNA. Kv11.1-wt channels expressed two protein bands corresponding to an immature core-glycosylated 135 kDa ER-resident Kv11.1 protein [wt-(I)], and a mature complex-glycosylated 155 kDa Kv11.1 band [wt-(M)]. Mutant Kv11.1 channels produced a single band at a slightly lower molecular weight (predicted to be 4 kDa smaller than Kv11.1-wt, thus approximately 131 kDa) corresponding to an immature core-glycosylated Kv11.1-mut protein [mut-(I)]. B: Densitometric analysis of total Kv11.1 protein (n = 4 experiments) demonstrated that Kv11.1-mut transfections resulted in significantly less total Kv11.1 protein expression than control or co-transfection (ANOVA *p<0.01). C,D: Reciprocal co-immunoprecipitation of Kv11.1-wt and Kv11.1-mut channels. Cells were transfected with a Kv11.1-wt construct lacking the HA-tag and Kv11.1-HA-mut. Co-immunoprecipitation was performed with anti-Kv11.1-wt antibody (C) (epitope corresponding to C-terminal 16 amino acids) or anti-HA antibody (D) for recognition of Kv11.1-mut. The two channel constructs strongly interacted. (Φ is a sample in which primary antibody was excluded during binding; IP: immunoprecipitation; IB: immunoblot).

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Western Blot, Transfection, Mutagenesis, Produced, Molecular Weight, Expressing, Cotransfection, Immunoprecipitation, Construct, Binding Assay

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: Electrophysiological properties of Kv11.1-wt and Kv11.1-mut channels were assessed using whole-cell patch clamping. A: Families of current tracings from −80 to +60 mV following 3 s step depolarizations. Kv11.1-wt currents were reduced following coexpression with Kv11.1-mut, indicating a dominant-negative suppression currents. Kv11.1-mut constructs were indistinguishable from GFP-transfected controls. B: The current-voltage relationship demonstrated that peak current amplitude is significantly reduced following coexpression (2.0 µg Kv11.1-wt, 57.7±4.6 pA/pF, n = 16; 1.0 µg Kv11.1-wt, 51.4±6.3 pA/pF, n = 14; 1.0 µg Kv11.1-wt+1.0 µg Kv11.1-mut, 25.3±2.0 pA/pF, n = 10, p<0.001 from Kv11.1-wt). Peak Kv11.1-mut currents were similar to GFP-transfected cells (2.0 µg Kv11.1-mut, 6.5±0.8 pA/pF, n = 15 versus 0.25 µg GFP, 5.1±0.5 pA/pF, n = 5). The current-voltage profile and C-type inactivation properties were identical following normalization (inset). C: Peak tail currents were measured immediately following repolarization. Kv11.1-wt+Kv11.1-mut tails were significantly reduced compared to control (2.0 µg Kv11.1-wt, 52.8±2.8 pA/pF, n = 16; 1.0 µg Kv11.1-wt, 43.5±3.9 pA/pF, n = 14; 1.0 Kv11.1-wt+1.0 µg Kv11.1-mut, 25.9±2.6 pA/pF, n = 10; p<0.01 from Kv11.1-wt). Tail currents were normalized and fit to a Boltzmann function to assess the steady-state activation properties (inset). No changes in slope or V1/2 parameters were observed.

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Dominant Negative Mutation, Construct, Transfection, Activation Assay

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: Channel kinetics were compared between Kv11.1-wt and Kv11.1-wt+Kv11.1-mut groups as no appreciable currents could be measured from Kv11.1-mut alone. There was no difference in channel activation (A), deactivation (B), contribution of the fast component to current decay (C), steady-state inactivation (D), fast inactivation (E) or recovery from inactivation (F).

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Activation Assay

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: The staining patterns for cells co-transfected with GFP (green) and HA-tagged Kv11.1 plasmids (CY3, red) were assessed using immunocytochemistry and confocal microscopy. A: Kv11.1-wt; B: Kv11.1-mut; C: co-expression of both plasmids. Untransfected cells served as negative controls (D). DAPI stained nuclei (blue) and phalloidin stained actin filaments (CY5, purple) were used to identify the nucleus and plasma membrane, respectively. White arrows indicate the location of line scans through the plasma membrane and perinuclear regions of merged images. Profile histograms indicate the fluorescence intensity for pixels along line scans for each group. Scale bar represents 20 µm.

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Staining, Transfection, Immunocytochemistry, Confocal Microscopy, Expressing, Fluorescence

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: Mature Kv11.1 protein expression was investigated using an external Kv11.1 epitope (CY3, red). A: Kv11.1-wt; B: Kv11.1-mut; C: co-expression of Kv11.1-wt and Kv11.1-mut. GFP-transfected cells served as negative controls (D); DAPI stained nuclei (blue); phalloidin stained actin filaments (CY5, purple). White arrows indicate the location of line scans through the plasma membrane and perinuclear regions of merged images. Profile histograms indicate the fluorescence intensity for pixels along line scans for each group. Black arrows indicate the approximate location of plasma membrane in the histogram panels. Scale bar represents 10 µm.

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Expressing, Transfection, Staining, Fluorescence

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: A/B: Cells were incubated at 30°C for 24 h and total Kv11.1 protein was assessed by Western blot. Reduced temperature did not change the intensity of the protein band nor cause the appearance of a Kv11.1-mut mature protein band. Co-transfection of non-HA-tagged Kv11.1-wt and HA-Kv11.1-mut (1.0 µg wt+1.0 µg HA-mut; in lanes 3 and 7) allowed for the specific identification of Kv11.1-mut protein (A; anti-HA antibody) and Kv11.1-wt protein (B; anti-Kv11.1 C-terminal antibody). C: Peak current-voltage relationship for Kv11.1-mut alone at 37°C and 30°C revealed no change in current density (Kv11.1-mut at 37°C, 6.5±0.8 pA/pF, n = 15 versus Kv11.1-mut at 30°C, 8.8±0.9 pA/pF, n = 4). D: Peak tail current amplitude did not significantly change with reduced temperature (Kv11.1-mut at 37°C, −1.8±0.3 pA/pF, n = 15 versus Kv11.1-mut at 30°C, 2.1±2.0 pA/pF).

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Incubation, Western Blot, Cotransfection

Journal: PLoS ONE

Article Title: Trafficking Defect and Proteasomal Degradation Contribute to the Phenotype of a Novel KCNH2 Long QT Syndrome Mutation

doi: 10.1371/journal.pone.0018273

Figure Lengend Snippet: A: Incubation with the proteasomal inhibitor lactacystin (20 µM) for 24 h enhanced the expression of immature Kv11.1-mut protein, but did produce a complex-glycosylated Kv11.1-mut protein. B: Densitometric analysis of total protein expression after lactacystin treatment (+) normalized to non-treated lysates (−). There was a significant increase in the expression of total Kv11.1-mut protein compared to the other groups (ANOVA *p<0.01). Untreated Kv11.1-mut cells (2.0 µg Kv11.1-mut, 1.53±0.19, n = 5) versus 2.0 µg Kv11.1-wt control (0.80±0.05) and 1.0 ug Kv11.1-wt+1.0 µg Kv11.1-mut (0.80±0.10, n = 3). C: Twenty-four h treatment with the Kv11.1 channel blocker E-4031 (5 µM) enhanced the mature Kv11.1 protein band in Kv11.1-wt and Kv11.1-wt+Kv11.1-mut groups, but did not elicit a mature Kv11.1-mut channel. D: Combined 24 h treatment with lactacystin (20 µM) and E-4031 (5 µM) did not significantly enhance Kv11.1-mut protein expression, nor did it rescue channel maturation in the Kv11.1-mut or Kv11.1-wt+Kv11.1-mut groups.

Article Snippet: After blocking, membranes were incubated with primary antibodies directed against the Kv11.1 C-terminus (APC-016, 1∶2000; Alomone, Jerusalem, Israel) or against the HA-epitope (H-9658, 1∶5000; Sigma) and secondary antibodies were horseradish peroxidase-conjugated (Jackson Immunoresearch, West Grove, PA).

Techniques: Incubation, Expressing

Journal: Frontiers in Pharmacology

Article Title: Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy

doi: 10.3389/fphar.2022.942769

Figure Lengend Snippet: I Kr currents and Kv11.1 protein were reduced in the myocardium in pCH. (A) Representative tail traces of I Kr before (left) and after application of E-4031 (2 μM) (right) in upper panel. Ventricular myocyte was pulsed as shown protocol. The lower panel showing representative tail traces recorded in myocytes from control (CON) and pCH (Ang II), respectively. (B) Summary data for I Kr tail current density-voltage relationship in control and pCH ( n = 10–14 cardiomyocytes from 3 to 5 hearts, * p < 0.05 versus CON). (C) Normalized current-voltage relationship for I Kr tail current. Curves were fit by Boltzmann function. (D) Representative I Ks traces recorded using the pulse protocol shown in the inset before (left) and after application of HMR1556 (2 μM) (right) in upper panel. The lower panel showing representative traces recorded in myocytes from control (CON) and pCH (Ang II), respectively. (E) Summary data for I Ks tail current density-voltage relationship in control and pCH ( n = 11–15 cardiomyocytes from 3 to 5 hearts). (F) Normalized current-voltage relationship for I Ks tail current. Curves were fit by Boltzmann function. (G) Representative immunoblots bands for mature and immature Kv11.1 proteins and corresponding summary data (CON n = 5, Ang II n = 7). (H) Representative immunoblots bands for Kv7.1 and KCNE1 proteins and corresponding summary data (CON n = 5, Ang II n = 7). GADPH was used as an internal control to normalize these bands. * p < 0.05, ** p < 0.01, and *** p < 0.001 versus CON. ns: not statistically significant.

Article Snippet: Antibodies against Kv7.1 (APC-022), KCNE1 (APC-163), or Kv11.1 (APC-016) were obtained from Alomone Labs, Jerusalem, Israel.

Techniques: Western Blot

Journal: Frontiers in Pharmacology

Article Title: Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy

doi: 10.3389/fphar.2022.942769

Figure Lengend Snippet: Nedd4-2-mediated ubiquitination of Kv11.1 was increased in pCH. (A) Representative immunoblots showing Nedd4-2, phosphorylated Nedd4-2 (p-Nedd4-2) and Rab11 proteins and corresponding quantifications of band densities in myocardium from control (CON) ( n = 5) and pCH (Ang II, n = 7). GADPH was used as an internal control to normalize the bands. (B) Representative blots immunoprecipitated (IP) by anti-Kv11.1, and western immunoblotting (IB) was performed by using anti-Nedd4-2 antibody. Quantification of band densities was shown as the ratio of Nedd4-2 to Kv11.1. (C) Representative blots immunoprecipitated by anti-Kv11.1, and western immunoblotting (IB) was performed by using anti-ubiquitin antibody. Quantification of band densities was shown as the ratio of ubiquitin to Kv11.1. (D) Proteins from control and pCH myocardium were immunoprecipitated with an anti-Kv7.1 or anti-IgG antibody, and IB was performed by using anti-Nedd4-2 antibody. IgG was used as negative controls. n = 3–4. * p < 0.05 and *** p < 0.001 versus CON. ns: not statistically significant.

Article Snippet: Antibodies against Kv7.1 (APC-022), KCNE1 (APC-163), or Kv11.1 (APC-016) were obtained from Alomone Labs, Jerusalem, Israel.

Techniques: Western Blot, Immunoprecipitation

Journal: Frontiers in Pharmacology

Article Title: Pharmacological suppression of Nedd4-2 rescues the reduction of Kv11.1 channels in pathological cardiac hypertrophy

doi: 10.3389/fphar.2022.942769

Figure Lengend Snippet: Overexpression of mNedd4-2 prevented the downregulation of Kv11.1 channels. (A) Representative I Kr tail current tracings elicited by voltage pulses shown in the inset from isolated ventricular myocytes. (B) Quantification of I Kr currents density-voltage relationship ( n = 9–24 from 3 to 5 hearts in each group). (C) Representative immunoblots showed that left ventricular tissue proteins were pulled down by anti-Kv11.1 or anti-IgG antibodies and probed by anti-ubiquitin antibody ( n = 3). (D) Representative I Ks currents elicited by a pulse protocol shown in the inset. (E) Summary data of I Ks currents density-voltage relationship ( n = 14–30 from 3 to 5 hearts in each group). * p < 0.05 versus CON, # p < 0.05 versus Ang II.

Article Snippet: Antibodies against Kv7.1 (APC-022), KCNE1 (APC-163), or Kv11.1 (APC-016) were obtained from Alomone Labs, Jerusalem, Israel.

Techniques: Over Expression, Isolation, Western Blot

Journal: The American Journal of Pathology

Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

doi: 10.1016/j.ajpath.2019.09.010

Figure Lengend Snippet: Kv11.1 channels are expressed in human lungs. Normal human lung hematoxylin and eosin (H&E) staining in a 41-year-old man (A) and 65-year-old woman (B). Shown are sections of the lung composed of terminal bronchiole (b) and thin-walled alveoli (a). Also shown is a thin layer of alveoli connective tissue and a multitude of pulmonary vessels (pv; arrows). C and D: Kv11.1 antibody staining of normal human lung in the 41-year-old man (C, right upper lobe) and 65-year-old woman (D, left lower lobe), with the structural elements denoted in the same manner as in A and B. E and F: Kv11.1 staining in bronchial smooth muscle layer (red arrows) and in the media of pulmonary arteries (PAs) of diameter >100 μm (black arrows) in the 41-year-old man (E) and 65-year-old woman (F). G and H: Arrows indicate the absence of Kv11.1 staining in small PAs (diameter <100 μm). I: Quantification of Kv11.1 channel expression [in arbitrary units (au)] in large and small PAs. J–M: Negative controls for E–H, correspondingly, with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated (red lines). n = 37 per group. *P < 0.05. Scale bars: 1 mm (A–D); 200 μm (E–H, J–M). Original magnification: ×16 (A–D); ×200 (E–H). IHC, immunohistochemistry.

Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

Techniques: Staining, Expressing, Immunohistochemistry

Journal: The American Journal of Pathology

Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

doi: 10.1016/j.ajpath.2019.09.010

Figure Lengend Snippet: Kv11.1 channel expression is increased in chronic obstructive pulmonary disease (COPD)-affected human lungs. A and B: Hematoxylin and eosin (H&E) staining of the lung tissue in individuals of the indicated age and sex showing alveoli emphysema (a), bronchiole (b), peribronchial fibrosis (asterisk), perivascular fibrosis, and pulmonary artery (PA) wall thickness (arrows). C–H: Kv11.1 antibody staining of media of large PAs (diameter >100 μm; black asterisks) and small PAs (diameter <100 μm; red asterisks) in six different individuals with COPD of the indicated age and sex. Tissue sections in C and E are from the right lower lobe; D, from the right upper lobe; F and G, from the left upper lobe; and H, from the left lower lobe of lungs. Arrows, pulmonary vessels; a, alveoli. I: Quantification of Kv11.1 channel expression (in arbitrary units; au) in small PAs of healthy and COPD-affected lungs. J–O: Negative controls for C–H, correspondingly, with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated (red lines). n = 37 (control); n = 79 (COPD). *P < 0.05. Scale bars: 1 mm (A and B); 200 μm (C–H, J–O). Original magnification: ×16 (A and B); ×200 (C–H). IHC, immunohistochemistry.

Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

Techniques: Expressing, Staining, Immunohistochemistry

Journal: The American Journal of Pathology

Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

doi: 10.1016/j.ajpath.2019.09.010

Figure Lengend Snippet: Kv11.1 channels are expressed in healthy rat lungs. A: Hematoxylin and eosin (H&E) staining of Sprague-Dawley rat lung tissue showing a normal structure of a bronchiole (b), alveoli (a), thin interstitial alveolar wall, and normal pulmonary arteries wall thickness (pv; arrows) in control rats. B: α-Smooth muscle actin antibody staining in the smooth muscle cell layer of a bronchiole (asterisk) and in the media of pulmonary arteries (PAs) at diameter >100 μm (black arrow). Absence of α-smooth muscle actin antibody staining in the media of PAs at diameter <100 mm (red arrows). C: Kv11.1 antibody staining in bronchial SMC layer (asterisk) and in the media of PAs at diameter >100 μm (black arrow). Images in ×400 magnification illustrate the absence of Kv11.1 antibody staining in small PAs (red arrows). D: Quantification of Kv11.1 channel expression in large and small PAs. E: Negative control for C with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated (red lines). n = 11 per group. *P < 0.05. Scale bars: 100 μm (A–C, right panels); 200 μm (A–C, left panels, E). Original magnification: ×200 (A–C, left panels); and ×400 (A–C, right panels). IHC, immunohistochemistry.

Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

Techniques: Staining, Expressing, Negative Control, Immunohistochemistry

Journal: The American Journal of Pathology

Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

doi: 10.1016/j.ajpath.2019.09.010

Figure Lengend Snippet: Kv11.1 channel expression increases in pulmonary arterial hypertension (PAH) rats. A: Hematoxylin and eosin (H&E) staining of lung tissue from Sprague-Dawley rats with PAH shows pulmonary arteries (PAs) wall thickness (arrows). After SU5416 injection, rats were kept in hypoxia for 3 weeks and then maintained in normoxia for 5 weeks. B: α-Smooth muscle actin (SMA) antibody staining in the media of small PAs (brown; arrows). C: Kv11.1 antibody staining in the media of small PAs (brown; arrows). D: Quantification of Kv11.1 channel expression (in arbitrary units; au) in small PAs of healthy and PAH rat lungs. E: Negative control for C with the primary antibody omitted and only the secondary antibody used. The mean of the data is indicated (red lines). n = 11 (control); n = 18 (PAH). *P < 0.05. Scale bars = 100 μm (A–C and E). Original magnification, ×400 (A–C and E). IHC, immunohistochemistry.

Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

Techniques: Expressing, Staining, Injection, Negative Control, Immunohistochemistry

Journal: The American Journal of Pathology

Article Title: Increased Smooth Muscle Kv11.1 Channel Expression in Pulmonary Hypertension and Protective Role of Kv11.1 Channel Blocker Dofetilide

doi: 10.1016/j.ajpath.2019.09.010

Figure Lengend Snippet: Kv11.1 channel expression gradually increases with the development of pulmonary arterial hypertension (PAH) in rats. A: Time course examination of Kv11.1 expression in PAH rats (brown; arrows). For this experiment Fischer rats were injected with SU5416, placed in hypoxia for 3 weeks, and then maintained in normoxia for 2 weeks to obtain time points of 0, 1, 2, 3, 4, and 5 weeks after the SU5416 injection. B: Negative control for the corresponding images in A with the primary antibody omitted and only the secondary antibody used. C: Quantification of the changes in Kv11.1 channel expression [in arbitrary units (au)] with PAH development in small pulmonary arteries (PAs). The mean of the data is indicated (red lines). n = 10. *P < 0.05. Scale bars = 100 μm (A and B). Original magnification, ×400 (A). IHC, immunohistochemistry.

Article Snippet: Tissue sections were subjected to hematoxylin and eosin (H&E) staining and immunohistochemistry (IHC) analysis using the α-smooth muscle actin primary antibody (1:300; catalog number ab5694; Abcam, Cambridge, UK) or Kv11.1 primary antibody (1:1000; catalog number APC-016; Alomone Laboratories, Jerusalem, Israel), followed by a secondary horseradish peroxidase–conjugated antibody (catalog number K4003; Agilent, Santa Clara, CA).

Techniques: Expressing, Injection, Negative Control, Immunohistochemistry